132 related articles for article (PubMed ID: 21603868)
21. Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX.
Yoshida Y; Hasegawa J; Nezu R; Kim YK; Hirota M; Kawano K; Izumi H; Kohno K
Cancer Sci; 2011 Mar; 102(3):578-82. PubMed ID: 21205083
[TBL] [Abstract][Full Text] [Related]
22. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
23. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
[TBL] [Abstract][Full Text] [Related]
24. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.
Kandutsch S; Klinger M; Hacker S; Wrba F; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2008 Nov; 34(11):1231-6. PubMed ID: 18272318
[TBL] [Abstract][Full Text] [Related]
25. Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen.
Cerny J; Hassan A; Smith C; Piperdi B
Clin Colorectal Cancer; 2009 Jan; 8(1):55-8. PubMed ID: 19203898
[TBL] [Abstract][Full Text] [Related]
26. Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines.
Fujiwara Y; Chayahara N; Mukohara T; Kiyota N; Tomioka H; Funakoshi Y; Minami H
Oncol Rep; 2013 Oct; 30(4):1802-6. PubMed ID: 23900774
[TBL] [Abstract][Full Text] [Related]
27. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
[No Abstract] [Full Text] [Related]
28. Cardiotoxicity and capecitabine: a case report.
Singer M
Clin J Oncol Nurs; 2003; 7(1):72-5. PubMed ID: 12629938
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant therapy for colorectal cancer: increasingly complex as patients age.
Sanoff HK; O'Neil BH
Oncology (Williston Park); 2009 Feb; 23(2):173-4. PubMed ID: 19323299
[No Abstract] [Full Text] [Related]
30. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer.
Schöber C; Papageorgiou E; Harstrick A; Bokemeyer C; Mügge A; Stahl M; Wilke H; Poliwoda H; Hiddemann W; Köhne-Wömpner CH
Cancer; 1993 Oct; 72(7):2242-7. PubMed ID: 8374883
[TBL] [Abstract][Full Text] [Related]
31. [Cardiotoxicity of 5-fluorouracil. Clinical relevance of palliative radiochemotherapy of malignant head-neck tumors].
Heib C; Schmidt HJ; Heib T; Lüer B; Stasche N
Laryngorhinootologie; 2001 May; 80(5):249-52. PubMed ID: 11417246
[TBL] [Abstract][Full Text] [Related]
32. 5-Fluorouracil Rechallenge After Cardiotoxicity.
Desai A; Mohammed T; Patel KN; Almnajam M; Kim AS
Am J Case Rep; 2020 Aug; 21():e924446. PubMed ID: 32860674
[TBL] [Abstract][Full Text] [Related]
33. Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer.
Franck C; Malfertheiner P; Venerito M
BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28536214
[TBL] [Abstract][Full Text] [Related]
34. [Risk factors for hyperammonemia during mFOLFOX6 treatment].
Misumi N; Goto T; Miyoshi T; Hiraike M; Shirasawa H; Saito O; Nishino T; Oudo M
Gan To Kagaku Ryoho; 2013 Apr; 40(4):483-7. PubMed ID: 23848016
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of Heart-Type Fatty Acid-Binding Protein and Myocardial Performance Index for Early Detection of 5-Fluorouracil Cardiotoxicity.
Turan T; Agac MT; Aykan AÇ; Kul S; Akyüz AR; Gökdeniz T; Gül İ; Cengiz E; Boyacı F; Erkan H; Akdemir R; Celik S
Angiology; 2017 Jan; 68(1):52-58. PubMed ID: 26980771
[TBL] [Abstract][Full Text] [Related]
36. Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study.
Dyhl-Polk A; Schou M; Vistisen KK; Sillesen AS; Serup-Hansen E; Faber J; Klausen TW; Bojesen SE; Vaage-Nilsen M; Nielsen DL
Oncologist; 2021 Mar; 26(3):e403-e413. PubMed ID: 32959474
[TBL] [Abstract][Full Text] [Related]
37. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk.
Lestuzzi C; Vaccher E; Talamini R; Lleshi A; Meneguzzo N; Viel E; Scalone S; Tartuferi L; Buonadonna A; Ejiofor L; Schmoll HJ
Ann Oncol; 2014 May; 25(5):1059-64. PubMed ID: 24558023
[TBL] [Abstract][Full Text] [Related]
38. Ultrasound tissue characterization by integrated backscatter for analyzing Fluorouracil induced myocardial damage.
Ceyhan C; Meydan N; Barutca S; Tekten T; Onbasili AO; Ozturk B; Unal S
Echocardiography; 2005 Mar; 22(3):233-8. PubMed ID: 15725158
[TBL] [Abstract][Full Text] [Related]
39. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
Peng J; Dong C; Wang C; Li W; Yu H; Zhang M; Zhao Q; Zhu B; Zhang J; Li W; Wang F; Wu Q; Zhou W; Yuan Y; Qiu M; Chen G
Cancer Commun (Lond); 2018 May; 38(1):22. PubMed ID: 29764506
[TBL] [Abstract][Full Text] [Related]
40. [Clinical significance of neutrophil to lymphocyte ratio in colorectal cancer patients receiving adjuvant chemotherapy combined with polysaccharide-K].
Yoshioka S; Kubo M; Yanagisawa K; Hata T; Takiuchi D; Hamano R; Minohata J; Kashiwazaki M; Miki H; Tsujie M; Konishi M; Yano H
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2086-8. PubMed ID: 24394021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
